Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized control trial of the conditioning BUCy regimen with fludarabincin instead of cyclophosphamide in allogeneic hematopoietic stem cell transplantation from identical siblings.

Next Previous
X
Search
Trial Profile

Randomized control trial of the conditioning BUCy regimen with fludarabincin instead of cyclophosphamide in allogeneic hematopoietic stem cell transplantation from identical siblings.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 26 Nov 2015

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fludarabine (Primary) ; Busulfan; Cyclophosphamide; Cytarabine
  • Indications Graft-versus-host disease; Haematological malignancies
  • Focus Therapeutic Use

    • Most Recent Events

    • 17 Jun 2012 Results presented at the 17th Congress of the European Haematology Association.
    • 21 May 2012 Planned end date changed from 1 Aug 2010 to 30 Dec 2010 as reported by Chinese Clinical Trial Register record.
    • 01 Sep 2009 Status changed from suspended to recruiting as reported by Chinese Clinical Trial Register.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top